Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Johnson and Johnson
Express Scripts
Dow

Last Updated: January 27, 2023

Insulin aspart - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for insulin aspart

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Amphastar Pharmaceuticals, Inc.Phase 2/Phase 3
DefymedN/A
McGill University Health Centre/Research Institute of the McGill University Health CentreN/A

See all insulin aspart clinical trials

Recent Litigation for insulin aspart

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novo Nordisk Inc. v. Alvogen, Inc.2022-03-03
Novo Nordisk Inc. v. Zydus Worldwide DMCC2022-03-03
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc.2022-03-03

See all insulin aspart litigation

Pharmacology for insulin aspart
Established Pharmacologic ClassInsulin Analog
Chemical StructureInsulin
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin aspart Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 See Plans and Pricing 2014-04-08 Company disclosures
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 See Plans and Pricing 2014-05-06 Company disclosures
Novo Nordisk Inc. NOVOLOG insulin aspart Injection 020986 See Plans and Pricing 2014-12-02 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for insulin aspart

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
99C0044 Belgium See Plans and Pricing PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
SPC/GB00/027 United Kingdom See Plans and Pricing PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
CA 2005 00046 Denmark See Plans and Pricing PRODUCT NAME: OPLOSELIGT INSULIN ASPART / PROTAMINKRYSTALLERET INSULIN ASPART 100E/ML I FORHOLDET 50/50
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.